USP Updates Guideline for Pending Monographs
The US Pharmacopeial (USP) Convention (Rockville, MD) has announced updates to the guideline for its pending monographs approach.
The US Pharmacopeial (USP) Convention (Rockville, MD) has announced updates to the guideline for its pending monographs approach. The revised guideline can streamline a drug’s entry into the US market by allowing manufacturers to submit information supporting a monograph before the Food and Drug Administration (FDA) grants full approval. After FDA approval, a pending monograph becomes official and moves into the US Pharmacopeia. The approach is similar to the FDA’s tentative approval, which has been used since 2004 to make available in overseas markets crucial drugs that are still on patent in the US (e.g., some medications for HIV/AIDS).
The pending standards approach helps drug manufacturers seeking FDA approval by creating an authorized pending monograph for a drug. This meets an FDA requirement that drugs be the subject of a compendial monograph. Drug manufacturers begin the pending standards process by submitting monograph information and materials to the USP for public comment. When the monograph is approved by the USP’s Council of Experts, the authorized pending monograph is made available on the USP’s web site.
The USP first implemented the pending monograph approach in early 2007. Comments received since then have lead to changes, including:
- Clarification of what constitutes intent to file an application with the FDA.
- Sponsors must promptly inform the USP of any changes resulting from the regulatory review and approval process so the pending standards monograph can be updated accordingly.
- USP will use its revision bulletin process to move a pending standards monograph to official status on product approval.
- USP must receive the bulk material necessary to develop any accompanying USP reference standards before posting a proposed pending standards monograph on its public web site.
Details of the policy and explanations of recent revisions are available on the USP web site.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Novartis Acquisition of Regulus Therapeutics is Complete
June 25th 2025A key property included in the acquisition is farabursen, an investigational next-generation oligonucleotide targeting the microRNA miR-17 with preferential kidney exposure, intended to treat people with autosomal dominant polycystic kidney disease.
